JP2022502514A - 徐放性カンナビノイド及びその製品 - Google Patents
徐放性カンナビノイド及びその製品 Download PDFInfo
- Publication number
- JP2022502514A JP2022502514A JP2021544978A JP2021544978A JP2022502514A JP 2022502514 A JP2022502514 A JP 2022502514A JP 2021544978 A JP2021544978 A JP 2021544978A JP 2021544978 A JP2021544978 A JP 2021544978A JP 2022502514 A JP2022502514 A JP 2022502514A
- Authority
- JP
- Japan
- Prior art keywords
- plastic material
- cannabinoid
- pcm
- cannabinoids
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 147
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 145
- 229940065144 cannabinoids Drugs 0.000 title description 80
- 238000013268 sustained release Methods 0.000 title description 4
- 239000012730 sustained-release form Substances 0.000 title description 4
- 229920000642 polymer Polymers 0.000 claims abstract description 67
- 239000000463 material Substances 0.000 claims abstract description 64
- 229920003023 plastic Polymers 0.000 claims abstract description 43
- 239000004033 plastic Substances 0.000 claims abstract description 43
- 239000002199 base oil Substances 0.000 claims abstract description 40
- 239000007788 liquid Substances 0.000 claims abstract description 36
- 239000002250 absorbent Substances 0.000 claims abstract description 21
- 230000002745 absorbent Effects 0.000 claims abstract description 21
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 34
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 34
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 34
- 229950011318 cannabidiol Drugs 0.000 claims description 34
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 32
- 239000003921 oil Substances 0.000 claims description 25
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 19
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 19
- 229960004242 dronabinol Drugs 0.000 claims description 18
- 229920001684 low density polyethylene Polymers 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 12
- 239000004702 low-density polyethylene Substances 0.000 claims description 12
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims description 7
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims description 7
- 229920000092 linear low density polyethylene Polymers 0.000 claims description 7
- 239000004707 linear low-density polyethylene Substances 0.000 claims description 7
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims description 7
- 239000005662 Paraffin oil Substances 0.000 claims description 6
- 239000011358 absorbing material Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 5
- 229920000098 polyolefin Polymers 0.000 claims description 5
- 229920003051 synthetic elastomer Polymers 0.000 claims description 5
- 239000005061 synthetic rubber Substances 0.000 claims description 5
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- VITZNDKHSIWPSR-HZPDHXFCSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-4-carboxylic acid Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=C(C(O)=O)C(CCCCC)=CC(O)=C3[C@@H]21 VITZNDKHSIWPSR-HZPDHXFCSA-N 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 238000009827 uniform distribution Methods 0.000 claims description 3
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 235000005273 Canna coccinea Nutrition 0.000 claims 1
- 240000008555 Canna flaccida Species 0.000 claims 1
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 235000019198 oils Nutrition 0.000 description 24
- 238000002386 leaching Methods 0.000 description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 240000004308 marijuana Species 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 239000004698 Polyethylene Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229920000573 polyethylene Polymers 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 10
- 230000007774 longterm Effects 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000806 elastomer Substances 0.000 description 6
- 229910021485 fumed silica Inorganic materials 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000000346 nonvolatile oil Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000006229 carbon black Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000010460 hemp oil Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 3
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002959 polymer blend Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019774 Rice Bran oil Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002621 endocannabinoid Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000008165 rice bran oil Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 244000198134 Agave sisalana Species 0.000 description 1
- 235000011624 Agave sisalana Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- KTPDAZGMXXWSMU-UHFFFAOYSA-N Cannabichromen Natural products CCCCc1cc(O)c2C=CC(C)(CCC=C(C)C)Oc2c1 KTPDAZGMXXWSMU-UHFFFAOYSA-N 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000006230 acetylene black Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 239000006231 channel black Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000006232 furnace black Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000006233 lamp black Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000002530 phenolic antioxidant Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004854 plant resin Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910021426 porous silicon Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000006234 thermal black Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
本出願は、その開示が参照により本明細書に組み込まれている、2018年10月15日出願の米国仮特許出願第62/745,628号についての、米国特許法第119条(e)による利益を請求している。
12 外面
14 外面
20 プラスチック-カンナビノイドマトリックス(PCM)
25 顆粒
27 構造用ポリマー
Claims (16)
- 構造用ポリマー内に埋め込まれた少なくとも1種のカンナビノイドを含むプラスチック材料であって、少なくとも1種のカンナビノイドが、治療上有効な速度で少なくとも1週間、プラスチック材料の外面を通って滲出するように配合されている、プラスチック材料。
- 少なくとも1種のカンナビノイドが、治療上有効な速度で少なくとも1か月間滲出するように配合されている、請求項1に記載のプラスチック材料。
- プラスチック材料が実質的に損なわれていないままである間に、少なくとも1種のカンナビノイドが滲出する、請求項1又は2に記載のプラスチック材料。
- プラスチック材料が、
構造用ポリマー内に埋め込まれた液体吸収材料と、
液体吸収材料中へ吸収されたキャリアオイルとを含み、
少なくとも1種のカンナビノイドが、キャリアオイルに溶解している、請求項1から3のいずれか一項に記載のプラスチック材料。 - 少なくとも1種のカンナビノイドが、カンナビジオール(CBD)、カンナビジオール酸(CBDA)、カンナビゲロール(CBG)、テトラヒドロカンナビノール(THC)、テトラヒドロカンナビノール酸(THCA)、カンナビクロメン(CBC)、及びカンナビジバリン(CBDV)からなる群のうちの1種、又は2種以上の組み合わせを含む、請求項1から4のいずれか一項に記載のプラスチック材料。
- 構造用ポリマーが、ポリオレフィン、ポリ塩化ビニル、熱可塑性ポリウレタン、シリコーンゴム、及び合成ゴムのうちの1種、又は2種以上の組み合わせを含む、請求項1から5のいずれか一項に記載のプラスチック材料。
- 構造用ポリマーが、LDPE及び/又はLLDPEを含む、請求項6に記載のプラスチック材料。
- キャリアオイルが、ヒト対象の皮膚に局所投与するのに適切である、請求項4から7のいずれか一項に記載のプラスチック材料。
- キャリアオイルが、パラフィン油及び/又は植物由来油を含む、請求項8に記載のプラスチック材料。
- 液体吸収材料が、多孔性ポリマー、シリカゲル、フュームドシリカ、カーボンブラック、及び活性炭からなる群より選択される1種、又は2種以上の組み合わせを含む、請求項4から9のいずれか一項に記載のプラスチック材料。
- 液体吸収材料が、構造用ポリマー内に顆粒状で埋め込まれている、請求項4から10のいずれか一項に記載のプラスチック材料。
- 液体吸収材料が、実質的に均一な分布で構造用ポリマー内に埋め込まれている、請求項11に記載のプラスチック材料。
- プラスチック材料が、接着性材料である、請求項1から12のいずれか一項に記載のプラスチック材料。
- プラスチック材料が、非接着性材料である、請求項1から12のいずれか一項に記載のプラスチック材料。
- プラスチック材料が、対象が装着するのに適切な形状に成形されている、請求項1から14のいずれか一項に記載のプラスチック材料を備える、プラスチックウェアラブルデバイス。
- 形状が、パッチ、ブレスレット、リストバンド、アンクレット、ネックレス、襟、アームバンド、及び靴インサートからなる群より選択される、請求項15に記載のプラスチックウェアラブルデバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745628P | 2018-10-15 | 2018-10-15 | |
US62/745,628 | 2018-10-15 | ||
PCT/IL2019/051120 WO2020079686A1 (en) | 2018-10-15 | 2019-10-15 | Slow release cannabinoids and products thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022502514A true JP2022502514A (ja) | 2022-01-11 |
JP7425072B2 JP7425072B2 (ja) | 2024-01-30 |
Family
ID=70283535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544978A Active JP7425072B2 (ja) | 2018-10-15 | 2019-10-15 | 徐放性カンナビノイド及びその製品 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20210361612A1 (ja) |
EP (1) | EP3723740A1 (ja) |
JP (1) | JP7425072B2 (ja) |
CN (1) | CN112996491A (ja) |
CA (1) | CA3077561A1 (ja) |
WO (1) | WO2020079686A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3723740A1 (en) | 2018-10-15 | 2020-10-21 | Vardi, Amnon | Slow release cannabinoids and products thereof |
ES2955484T3 (es) * | 2019-06-25 | 2023-12-01 | Ab7 Sante | Dispositivo en forma de una matriz polimérica a base de cannabinoides |
MX2023000316A (es) * | 2020-08-17 | 2023-02-22 | Pike Therapeutics Inc | Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58206516A (ja) * | 1982-05-25 | 1983-12-01 | アルザ・コ−ポレ−シヨン | 経皮治療用装具 |
JPS62158724A (ja) * | 1985-12-30 | 1987-07-14 | Nippon Petrochem Co Ltd | 薬剤含有粒状プラスチツクの製造法 |
JPH06200219A (ja) * | 1992-12-28 | 1994-07-19 | Nippon Petrochem Co Ltd | 薬剤含有粘着シート |
US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
JP2005307120A (ja) * | 2004-04-26 | 2005-11-04 | Mitsubishi Chemicals Corp | 徐放剤及びそれを用いた徐放材 |
JP2018507262A (ja) * | 2015-03-02 | 2018-03-15 | アフギン ファーマ, エルエルシーAfgin Pharma, Llc | カンナビノイドを用いた、局所局部的神経作用療法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2729539B1 (fr) | 1995-01-23 | 1997-04-11 | Virbac Lab | Dispositif a liberation controlee de substances chimiques, destine a etre fixe sur un animal et procede de preparation dudit dispositif |
US6632522B1 (en) * | 1995-02-16 | 2003-10-14 | 3M Innovative Properties Company | Blended pressure-sensitive adhesives |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
FR2901132B1 (fr) | 2006-05-18 | 2011-04-01 | Ab7 Ind | Dispositif de transfert dermique d'un actif. |
US8758826B2 (en) * | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
EP3054934B1 (en) * | 2013-10-07 | 2024-05-22 | Teikoku Pharma USA, Inc. | Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions |
US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
WO2016022936A1 (en) * | 2014-08-07 | 2016-02-11 | Murty Pharmaceuticals, Inc. | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
US9375417B2 (en) * | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
US20160338974A1 (en) * | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
EP3355874A4 (en) * | 2015-09-30 | 2019-06-12 | George Edward Hoag | TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF |
US10828265B2 (en) * | 2016-12-09 | 2020-11-10 | The Regents Of The University Of California | Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery |
US11247032B1 (en) * | 2017-09-07 | 2022-02-15 | Massachusetts Mutual Life Insurance Company | Wearable band for transdermal drug delivery |
EP3723740A1 (en) | 2018-10-15 | 2020-10-21 | Vardi, Amnon | Slow release cannabinoids and products thereof |
-
2019
- 2019-10-15 EP EP19872806.5A patent/EP3723740A1/en active Pending
- 2019-10-15 JP JP2021544978A patent/JP7425072B2/ja active Active
- 2019-10-15 WO PCT/IL2019/051120 patent/WO2020079686A1/en unknown
- 2019-10-15 US US16/760,496 patent/US20210361612A1/en not_active Abandoned
- 2019-10-15 CN CN201980073810.0A patent/CN112996491A/zh active Pending
- 2019-10-15 CA CA3077561A patent/CA3077561A1/en active Pending
-
2022
- 2022-07-13 US US17/863,428 patent/US11672778B2/en active Active
-
2023
- 2023-04-30 US US18/309,804 patent/US12059401B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58206516A (ja) * | 1982-05-25 | 1983-12-01 | アルザ・コ−ポレ−シヨン | 経皮治療用装具 |
JPS62158724A (ja) * | 1985-12-30 | 1987-07-14 | Nippon Petrochem Co Ltd | 薬剤含有粒状プラスチツクの製造法 |
JPH06200219A (ja) * | 1992-12-28 | 1994-07-19 | Nippon Petrochem Co Ltd | 薬剤含有粘着シート |
US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
JP2005307120A (ja) * | 2004-04-26 | 2005-11-04 | Mitsubishi Chemicals Corp | 徐放剤及びそれを用いた徐放材 |
JP2018507262A (ja) * | 2015-03-02 | 2018-03-15 | アフギン ファーマ, エルエルシーAfgin Pharma, Llc | カンナビノイドを用いた、局所局部的神経作用療法 |
Also Published As
Publication number | Publication date |
---|---|
CA3077561A1 (en) | 2020-04-15 |
CN112996491A (zh) | 2021-06-18 |
US20230310365A1 (en) | 2023-10-05 |
US11672778B2 (en) | 2023-06-13 |
US20210361612A1 (en) | 2021-11-25 |
US12059401B2 (en) | 2024-08-13 |
JP7425072B2 (ja) | 2024-01-30 |
EP3723740A4 (en) | 2020-10-21 |
EP3723740A1 (en) | 2020-10-21 |
US20220347154A1 (en) | 2022-11-03 |
WO2020079686A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11672778B2 (en) | Slow release cannabinoids and products thereof | |
US8652511B2 (en) | Transdermal delivery patch | |
CN102858379B (zh) | 粘合剂组合物 | |
US20110318405A1 (en) | Chemical Combination and Method for Increasing Delivery of Coenzyme Q10 | |
CA2633109A1 (en) | Topical pharmaceutical compositions | |
CA2762770A1 (en) | Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing | |
CN110475548A (zh) | 模块化透皮递送系统以及相关制备和使用方法 | |
CA3110849A1 (en) | Pharmaceutical formulation and system and method for delivery | |
CN105053047A (zh) | 香草驱蚊中药组合物 | |
US20180311181A1 (en) | Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety | |
KR102077954B1 (ko) | 첩부제 | |
US20040170672A1 (en) | Transdermal therapeutic system for administration of partial dopamine-d2 agonists | |
US11672755B2 (en) | Extended release plastic formulation | |
CN104394858A (zh) | 经皮吸收促进剂及含有其的贴附剂 | |
US20220339119A1 (en) | Transdermal medicament | |
EP1368008B1 (de) | Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol | |
JP5192722B2 (ja) | 外用貼付剤 | |
DE102015212496A1 (de) | Wärmepads mit ringförmigen Wärmezellen | |
JP4365533B2 (ja) | アルコール中毒症の治療のためのデオキシペガニン含有医薬組成物 | |
US11969508B2 (en) | Extended release plastic formulation | |
US20100247616A1 (en) | Patch and patch preparation | |
JP6019441B2 (ja) | 経皮吸収型介護臭ケアテープ剤 | |
JPS59184123A (ja) | ゴム系粘着性膏体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210527 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231101 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231225 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7425072 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |